1BLANK J. Sir James Black: learning by doing [J]. Interview. Molecular Interventions, 2004, 4(3) : 139-142.
2MCGREGORA. James Whyte Black. 14 June 1924-22 March 2010 [J]. Br J Pharmacol, 2010, 160 (Suppl. 1): S3-S4.
3BLACK J W, FISHER E W, SMITH A N. The effects of 5-hydroxytryptamine on gastric secretion in anaesthetized dogs [J]. J Physiol, 1958, 141(1):27-34.
4QUIRKEV. Putting theory into practice: James Black, receptor theory and the development of the beta- blockers at ICI, 1958-1978 [J]. Med Hist, 2006, 50(1) :69-92.
5AHLQUIST R P. A study of the adrenotropic receptors[J]. Am J Physiol, 1948, 153(3):586-600.
6BLACK J W, CROWTHER A F, SHANKS R G, et al. A new adrenergic betareceptor antagonist [J]. Lancet, 1964, 1(7342):1080-1081.
7STAPLETON M P. Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascu- lar pharmacology [J]. Tex Heart Inst J, 1997, 24(4):336-342.
8Black J W, Duncan W A, Durant C J, et al. Definition and antagonism of histamine H2-receptors[J]. Nature, 1972, 236(5347) :385-390.
9MASSARRAT S. Marshall and Warren: the Nobel Prize winners in medicine in 2005 [J]. Arch Iran Med, 2006, 9(2) :177-180.
10GANELLIN R, DUNCAN W. Obituary: James Black (1924-2010)[J]. Nature, 2010, 464(7293):1292.
